EbrahimSDelpassandMD

Clinical Trials

• Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer Start of enrollment: 2005 Jun 01

  Completed

  Not Applicable

• Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Start of enrollment: 2005 Aug 01

  Completed

  Phase 2, Phase 3

• 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Start of enrollment: 2010 Oct 27

  Completed

  Phase 2

• A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Start of enrollment: 2012 Sep 06

  Completed

  Phase 3

• 68-Ga-DOTATATE PET-CT Scan for Diagnosis of Primary and Metastatic Somatostatin Receptor-positive Neuroendocrine Tumors (NETs) Start of enrollment: 2013 Mar 01

  Completed

  Not Applicable

• Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy Start of enrollment: 2017 Jul 12

  Terminated

  Phase 2

• Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET Start of enrollment: 2018 Feb 05

  Recruiting

  Phase 1

• Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE Start of enrollment: 2018 Aug 23

  Completed

  Phase 3

• Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). Start of enrollment: 2021 Dec 16

  Recruiting

  Phase 2

  Roles: Contact

• Join now to see all